| Name | JNJ-38877618 |
| Description | JNJ-38877618 (OMO-1) is an effective and highly selective inhibitor of Met kinase (IC50s: 2 and 3 nM for wild type and mutant Met, respectively). |
| In vitro | JNJ-38877618 shows nM potency against Met Ampl/mutant and therapy-resistant models. JNJ-38877618 has nM binding affinity (Kd=1.4 nM) and enzyme inhibitory activity against wt and M1268T mutant Met (2 and 3 nM IC50). Met inhibitory effects are assessed in proliferation, colony formation, and motility assays. |
| In vivo | JNJ-38877618 effectively induces regression in substantial Met-amplified EBC-1 SqNSCLC by dose- and time-dependently inhibiting Met kinase activation, with the inhibition lasting significantly longer than its plasma presence. It entirely halts tumor growth in three distinct models: SNU5 Met amp gastric, U87-MG HGF autocrine glioblastoma, and Hs746T Met exon 14 skipping mutant gastric cancer. Additionally, combination therapies are well tolerated and enhance EGFR-targeted treatments[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 4.5 mg/mL (12.02 mM), Sonication is recommended.
|
| Keywords | JNJ 38877618 | OMO 1 | Inhibitor | c-Met/HGFR | JNJ38877618 | JNJ-38877618 | inhibit | OMO1 |
| Inhibitors Related | Cabozantinib | Capmatinib 2HCl | SGI-7079 | (±)-Norcantharidin | L-Ascorbic acid 2-phosphate trisodium | Crizotinib | Amuvatinib | Norcantharidin | Cabozantinib S-malate | Capmatinib xHCl | Bacitracin Zinc | Capmatinib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
